why choose us

First received: December 11, 2023

Clinical Trial: A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Healthy Male Participants

Study Type: INTERVENTIONAL


Official Title: An Open-Label, Parallel-Group Phase I Study to Evaluate the Relative and Absolute Bioavailability of Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy

Brief Summary: This is a Phase I, open-label, non-randomized, parallel-group, single-dose study in healthy adult male participants.The aim is to investigate the relative bioavailability (rBA) of NXT007 among subcutaneous (SC) injection sites (abdomen, upper arm, and thigh) and the absolute bioavailability (aBA) of SC NXT007 administration.In addition, the pharmacodynamic, safety, tolerability, and immunogenicity of a single dose of NXT007 following SC or intravenous (IV) administration are assessed.

Read more